Program
Akt Inhibitor NTQ1062
Also written as “NTQ1062+Fulvestrant”, “NTQ1062” and “NTQ1062 with Fulvestrant”.
In Sino Biopharmaceutical’s pipeline, AKT抑制剂
. Its studies are mostly in Breast Neoplasms, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 32 open or running | phase 3since Jan 16, 2026 | Nov 23, 2023 | Aug 31, 2028phase 3 · NCT07393321 |
- Named in Sino Biopharmaceutical’s own pipeline as
NTQ1062
, phase 3, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 23, 2023First studies: 2 phase 1 studiesFirst studyNCT06172309, NCT06172322
- Jan 16, 2026Phase 3 study in Breast NeoplasmsPhase 3 reachedNCT07393321 · 210 planned
Ahead
- Aug 31, 2028Primary completion: phase 3 study in Breast NeoplasmsNCT07393321
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07393321Breast Neoplasms | 3 | Not yet recruiting | Aug 31, 2028 | 210 |
| NCT06172322HR Positive/HER-2 Negative Breast Cancer · China | 1 | Recruiting | Apr 2025 | 42 |
| NCT06172309Advanced Solid Tumors · China | 1 | Completed | Apr 20, 2024 | 32 |
How it is read
Names in the registry
- “NTQ1062+Fulvestrant”, 1 entry
- “NTQ1062”, 1 entry
- “NTQ1062 with Fulvestrant”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.